Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III clinical studies including immunotherapy for gynaecological malignancies. In this video, she speaks about the ASCO Late Breaker Abstract ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.
Overview:
This is a 4-arm, Phase 3 randomized, global, double-blind, placebo-controlled research investigating rucaparib with nivolumab as maintenance treatment after response to front-line treatment in patients with newly diagnosed ovarian cancer. The homologous recombination (HR) status of tumor samples will be used to assess therapy response.